Positrigo receives FDA approval for NeuroLF

Positrigo, is a pioneer in nuclear medical imaging technologies, aiming to advance functional brain imaging. Its first product, NeuroLF, is an ultra-compact brain Positron Emission Tomography (PET) scanner designed to assist in diagnosing and monitoring of brain related disorders like Alzheimer’s disease (AD), Brain Tumors, Epilepsy, Parkinson’s disease and others.

With AD being the most common form of dementia, early diagnosis is of utmost importance and PET imaging of the brain is essential for the accurate diagnosis of AD patients. However, the currently available PET scanners are large and always combined with MRI or CT. The purchase and maintenance costs are significant and in addition a lot of space is required which limits the availability of these devices. With the NeuroLF system, the startup supports a paradigm shift in medical imaging where a dedicated device allows for imaging of a particular body part or organ, such as the brain. By harnessing the advancement in mechanical, electronic and software developments, this system requires only minimal space and no special room modifications. It further allows patients to receive a brain scan in a seated position and enables functional imaging at the point-of-care.

NeuroLF has now obtained clearance from the U.S. Food and Drug Administration (FDA). This lays the foundation for the ETH spinoff to enter the US market, where a growing demand for PET systems is apparent. With the existing pre-orders and the strong demand from customers worldwide, the company is gearing up its production capabilities to deliver to its first customers.

“It is not the first device of its kind which receives market clearance in the US, but we believe that our patient-centric and customer-driven design and development efforts over the last couple of years, brought us into the pole position to offer the best imaging solution to address the increased demand of brain PET scans,” says Dr. Jannis Fischer, co-founder and CEO.

The development of a dedicated brain PET device is very timely as just earlier this month another disease-modifying therapy for AD received FDA approval, making it the third medication after two other therapies came to market last year in the US.

(Press release/RAN)